Risk factors for cardiovascular disease in type 1 diabetes

Diabetes

Volumn 65, Issue 5, 2016, Pages 1370-1379

  Nathan, David M ^a   Bebu, Ionut ^b   Braffett, Barbara H ^b   Lachin, John M ^b   Orchard, Trevor J ^c   Cowie, Catherine C ^d   Lopes Virella, Maria ^e   Schutta, Mark ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FAMILY HISTORY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MICROALBUMINURIA; PRIORITY JOURNAL; PULSE RATE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; AGING; BIOLOGICAL MODEL; BLOOD; CANADA; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; INCIDENCE; LONGITUDINAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGING; CANADA; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INCIDENCE; LONGITUDINAL STUDIES; MALE; MODELS, CARDIOVASCULAR; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84964584279     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1517     Document Type: Article

References (43)

1. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006;29:2528-2538
2. Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish Registry Linkage Study. PLoS Med 2012;9:e1001321
3. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U. K.: a cohort study using the general practice research database. Diabetes Care 2006;29:798-804
4. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987;30:144-148
5. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26:1374-1379
6. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006;55:1463-1469
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
8. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
9. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530-545
10. The DCCT/EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
11. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267-2271
12. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000;49:626-632
13. Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2014;37:39-43
14. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000;21:552-560
15. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. 2nd ed. Hoboken, NJ, Wiley, 2011
16. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, Berlin, Springer, 2000
17. Claeskens G, Hjort NL. Model selection and Model Averaging. Cambridge, New York, Cambridge University Press, 2008
18. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997;16:385-395
19. Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20, 985 patients with type 1 diabetes: an observational study. Lancet 2011;378:140-146
20. Miller RG, Secrest AM, Ellis D, Becker DJ, Orchard TJ. Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2013;36:3999-4006
21. Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes. Best Pract Res Clin Endocrinol Metab 2014;28:325-338
22. Tolonen N, Forsblom C, Mäkinen VP, et al.; FinnDiane Study Group. Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: the FinnDiane study. Diabetes Care 2014;37:2374-2382
23. American Diabetes Association. Standards of Medical Care in Diabetes-2015. Diabetes Care 2015;38(Suppl.):3S1-S93
24. May O, Arildsen H, Damsgaard EM, Mickley H. Cardiovascular autonomic neuropathy in insulin-dependent diabetes mellitus: prevalence and estimated risk of coronary heart disease in the general population. J Intern Med 2000;248:483-491
25. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-765
26. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775, 385 individuals and 12, 539 strokes. Lancet 2014;383:1973-1980
27. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858, 507 individuals and 28, 203 coronary events. Diabetologia 2014;57:1542-1551
28. Mozaffarian D, Benjamin EJ, Go AS, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015;131:e29-e322
29. Ferrara A, Mangione CM, Kim C, et al.; Translating Research Into Action for Diabetes Study Group. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care 2008;31:69-74
30. Larkin ME, Backlund JY, Cleary P, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabet Med 2010;27:451-458
31. Williams K, Tchernof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes 2008;57:3289-3296
32. Peters SA, Huxley RR, Sattar N, Woodward M. Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. Curr Cardiovasc Risk Rep 2015;9:36
33. Costacou T, Evans RW, Orchard TJ. High-density lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol 2011;5:387-394
34. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006;91:2906-2912
35. Conway B, Miller RG, Costacou T, et al. Adiposity and mortality in type 1 diabetes. Int J Obes 2009;33:796-805
36. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008;31:1360-1366
37. The DCCT Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415-1427
38. Williams KV, Erbey JR, Becker D, Orchard TJ; The Epidemiology of Diabetes Complications Study. Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. Diabetes Care 1999;22:1084-1091
39. Pedersen MM, Christensen CK, Mogensen CE. Long-term (18 year) prognosis for normo- and microalbuminuric type 1 (insulin-dependent) diabetic patients. Diabetologia 1992;35(Suppl.):A60
40. Matsushita K, Coresh J, Sang Y, et al.; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3:514-525
41. DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014;2:793-800
42. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-753
43. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC Study 30-year follow-up. Diabetes Care 2016;39:790-797